InsiderTrades

Form 4 for SPRY ARS Pharmaceuticals, Inc.

Accepted 2022-11-10 00:00:00 ET · period of report 2022-11-08 · accession 0001209191-22-056447 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-11-10 2022-11-08 SPRY Chakma Justin Chief Business Off A - Grant — +236.4K 236.4K New —
DM 2022-11-10 2022-11-08 SPRY Chakma Justin Chief Business Off A - Grant — +603.8K 236.4K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-11-08 A A 236,380 — 236,380 D — — (F1) Received in exchange for 200,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.
2 Derivative Stock option (right to buy) 2022-11-08 A A 82,733 — 82,733 D $1.44 · — to 2031-12-14 82,733 Common Stock (F4) Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F6) Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement. (F2) 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
3 Derivative Stock option (right to buy) 2022-11-08 A A 48,260 — 48,260 D $0.84 · — to 2029-12-17 48,260 Common Stock (F4) Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F5) Received in exchange for a stock option to acquire 40,833 shares of common stock of ARS with the exercise price of $0.99 per share pursuant to the Merger Agreement. (F2) 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
4 Derivative Stock option (right to buy) 2022-11-08 A A 236,380 — 236,380 D $0.84 · 2022-11-08 to 2029-07-05 236,380 Common Stock (F4) Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F3) Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS under the Merger Agreement.
5 Derivative Stock option (right to buy) 2022-11-08 A A 236,380 — 236,380 D $0.84 · — to 2029-07-05 236,380 Common Stock (F4) Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F3) Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS under the Merger Agreement. (F2) 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.